SCHEDULE 13G/A: Light Irrevocable Trust Discloses 6.9% Stake in Design Therapeutics

Light Irrevocable Trust #1, along with Jason Howerton, has filed an amended Schedule 13G disclosing a 6.9% beneficial ownership stake in Design Therapeutics, Inc. as of December 31, 2024.

Summary

• Light Irrevocable Trust #1 dated April 22, 2019, and Jason Howerton, have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Design Therapeutics, Inc.
• As of December 31, 2024, Light Irrevocable Trust #1 beneficially owns 3,834,355 shares of Design Therapeutics, Inc. Common Stock.
• This ownership represents 6.9% of the total class of securities outstanding.
• The percentage is calculated based on 56,621,037 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q filed on November 7, 2024.
• Jason Howerton, who was the sole trustee of Light Trust until October 1, 2024, is also a reporting person but holds 0.0% beneficial ownership as of the filing date.
• The Light Irrevocable Trust #1 has shared voting and shared dispositive power over all 3,834,355 shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by a significant shareholder, providing transparency into the ownership structure of Design Therapeutics, Inc. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant beneficial owner's stake in the company, which can be relevant for understanding shareholder base stability.

Key Dates

Keywords

Design Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Light Irrevocable Trust, Jason Howerton, Institutional Ownership